WHAT IS BEAT AML?
In 2016, The Leukemia & Lymphoma Society (LLS) launched the Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced technology to examine the genetic make-up of each patient’s cancer and then matches patients to the most promising targeted treatment.
What has Beat AML accomplished?
- Improved survival for AML patients enrolled in a Beat AML study (compared to standard chemotherapy)
- Facilitated precision medicine treatment for over 540 AML patients in a Beat AML sub-study
- Sequenced AML genomes for over 1,600 patients
- Offered clinical studies to treat 15 unique types of AML
-
Data was used to update NCCN guidelines for newly diagnosed AML patients with IDH2 mutations with enasidenib
-
Data used to initiate 2 registration Phase 3 studies
What makes the Beat AML Master Clinical Trial groundbreaking?
- LLS brought together a range of blood cancer experts to collaborate like never before to disrupt the status quo in AML treatment
- The master clinical trial protocol allows different patients, depending on the genetic features of their AML, to enroll in Beat AML sub-studies using different treatment approaches
- Advanced technology provides genomic analysis to match patients to precision treatment within seven days
- Precision medicine approach moves people away from one-size-fits-all chemotherapy
To learn more about Beat AML: https://www.lls.org/bringing-precision-medicine-aml-patients
